Table 5 Association between patient factors, disease type, and melphalan dose with severity of GI symptoms
Variable | Upper GI symptoms < grade 2 (n = 28) | Upper GI symptoms ≥ grade 2 (n = 19) | p value | Diarrhea ≤ grade 2 (n = 27) | Diarrhea grade 3 (n = 20) | p value |
|---|---|---|---|---|---|---|
Age | 0.312 | 0.474 | ||||
< 50 | 12(42.9) | 11(57.9) | 12(44.4) | 11(55) | ||
≥ 50 | 16(57.1) | 8(42.1) | 15(55.6) | 9(45) | ||
Sex | 0.108 | 0.058 | ||||
Male | 17(60.7) | 7(36.8) | 17(63) | 7(35) | ||
Female | 11(39.3) | 12(63.2) | 10(37) | 13(65) | ||
Disease | 0.440 | 0.642 | ||||
Lymphoma | 13(46.4) | 11(57.9) | 13(48.1) | 11(55) | ||
Multiple myeloma | 15(53.6) | 8(42.1) | 14(51.9) | 9(45) | ||
Melphalan dose | 0.440 | 0.642 | ||||
140 mg/m2 | 13(46.4) | 11(57.9) | 13(48.1) | 11(55) | ||
200 mg/m2 | 15(53.6) | 8(42.1) | 14(51.9) | 9(45) |